We study cancer in narrow cohorts, excluding comorbidities. By doing so we miss critical info that can lead to earlier identification/treatment. While we must stratify samples, we can do so and include comorbidities that lead to disease pathways.
Voting on Ideas
Vote for your favorite ideas by clicking on the up arrow.To undo an upvote, simply click the arrow again. This second click removes your vote.